Use of Antisense Oligodeoxynucleotides for Inhibiting JC Virus

Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the brain caused by the polyomavirus JC (JCV) under immunosuppressive conditions. It is pathologically characterized by progressive damage of white matter of the brain by destroying oligodendrocytes at multiple locations. Clinically, PML symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. The prognosis of PML is generally poor. No effective therapy for PML has been established. The current strategies to develop a PML therapy focus on blocking viral infection or inhibiting JCV replication. Antisense oligodeoxynucleotides (ODNs) that can block JCV replication and multiplication have been identified and optimized. Use of the ODNs provide a method of inhibiting JCV replication and thereby provide a treatment for PML. IC: NINDSNIH Ref. No.: E-547-2013/0TAB No:  TAB-2681 Advantages: Low cost PML therapeutics Lower cost JCV diagnostics Ease of synthesis Applications: JCV/PML Therapeutics JCV Diagnostics JCV Kits Development Status: Pre-clinical In vitro data available In vivo data available (animal) Provider Technology ID: 2681Updated On: Feb 11, 2016Date Published: Tuesday, December 3, 2013Patent Application: 61/879,833PCT/US2014/056655Patent Authority: USPCTLead Inventor: Inventor IC: NINDSNINDSNINDSNINDSNINDSInventor Lab URL: http://irp.nih.gov/pi/avin...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research